Braveheart
3 known investors
Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions. The company focuses on improving the standard of care for patients with these disease types.
Founders & leadership
TM
Travis Murdoch, M.D.Chief Executive Officer and Board Director
Investors · 3
Funding
SEC filings, press & company announcementsSource: company announcements and press reports — follow each round's link for the claim.
Competitors · 4
by search overlap
Hello Heart7 shared keywordsHello Heart is an AI company that builds preventive heart health solutions to help people lower their cardiovascular risk. The company serves individuals and healthcare organizations focused on reducing heart disease, the leading cause of death.
ByHeart6 shared keywordsByHeart is an infant formula company navigating an FDA return-to-market process following a product outbreak investigation. The page addresses regulatory findings, corrective actions, and manufacturing controls rather than describing the full product line.
March Biosciences6 shared keywordsMarch Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments. The company focuses on developing therapeutics in the cell and gene therapy space.
Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Braveheart for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengruifiercebiotech.com · Aug 2026
Cardiac drug developer Braveheart banks more than $382M in IPO | BioPharma Divebiopharmadive.com · Aug 2026
Braveheart Bio IPO: Shares in the cardiovascular drug developer are now available – Oninvesten.oninvest.com · Aug 2026
Wonder Raises $650M Series D at $9B Valuation — Food & Beverage Magazinefb101.com · Jul 2026
Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWiregeekwire.com · Jul 2026Frequently asked questions
- What does Braveheart do?
- Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions. The company focuses on improving the standard of care for patients with these disease types.
- Who are Braveheart's investors?
- Braveheart's investors include Andreessen Horowitz, Frazier Life Sciences, OrbiMed.